Saturday 17 October 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
29.58
0.14
+0.48%
Follow PFE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 4.97% | 8.28% | 8.87% | 10.59% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 5 | 6 | 7 | |
| 2.13% | 3.60% | 3.69% | 4.59% | ||
ROIC |
6.30% | 6.41% | 6.45% | 6.13% | |
Return on Tangible Assets |
15.62% | 26.87% | 30.80% | 33.65% | |
Average Days of Receivables |
71.57 | 72.55 | 69.26 | 82.90 | |
Free Cash Flow per Share |
1.93 | 1.67 | 1.60 | 1.83 | |
Free Cash Flow |
10,985.00 | 9,483.00 | 9,075.00 | 10,376.00 | |
Capital Expenditures |
(2,416.00) | (2,501.00) | (2,629.00) | (2,701.00) | |
| Other line items | |||||
Cash ROIC |
6.85% | 5.65% | 5.49% | 6.11% | |
Accounts Receivable Turnover |
5.19 | 5.18 | 5.36 | 4.37 | |
Accounts Payable Turnover |
3.51 | 3.44 | 2.96 | 3.23 | |
Inventory Turnover |
1.58 | 1.56 | 1.49 | 1.44 | |
Average Days of Payables |
97.87 | 98.07 | 119.04 | 109.78 | |
Days of Inventory on Hand |
212.48 | 232.17 | 242.03 | 250.59 | |
Tax Rate |
0.04 | (0.05) | 0.04 | 0.07 | |
Research and Development Expense of Revenue |
17.35% | 16.94% | 16.68% | 16.35% | |
Selling, General and Administrative Expense of Revenue |
21.54% | 21.68% | 22.04% | 22.15% | |
Share Based Compensation of Revenue |
1.49% | 1.42% | 1.28% | 1.20% | |
Operating CF/Net income |
3.09 | 1.60 | 1.51 | 1.33 | |
Depreciation/Fixed assets |
0.35 | 0.34 | 0.34 | 0.35 | |
Capex/Depreciation |
(0.37) | (0.38) | (0.40) | (0.40) | |
Revenue per Share |
11.18 | 11.13 | 11.01 | 11.04 | |
Operating CF per Share |
2.35 | 2.11 | 2.06 | 2.30 | |
Capex per Share |
(0.42) | (0.44) | (0.46) | (0.48) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.04 |
Columns are period end dates